Showing results (51-60 of 55) with videos related to
Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
Maturitas|December 6, 2025
Age-related differences in patient preferences for adjuvant chemotherapy for high-risk endometrial cancerFamke C Wakkerman, Cathalijne C B Post, Jan Willem M Mens, et al.Obstetrical & Gynecological Survey|December 30, 2025
Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 TrialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.The Lancet. Oncology|September 8, 2025
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.Journal of Computational Chemistry|May 16, 2009
CHARMM: the biomolecular simulation programB R Brooks, C L Brooks, A D Mackerell, et al.International Journal of Radiation Oncology, Biology, Physics|November 1, 2020
Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 TrialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.Pageof 6